• SPX
  • $5,408.42
  • -1.73 %
  • -$94.99
  • DJI
  • $40,345.41
  • -1.01 %
  • -$410.39
  • N225
  • $35,477.16
  • -2.51 %
  • -$914.09
  • FTSE
  • $8,181.47
  • -0.73 %
  • -$60.24
  • IXIC
  • $16,690.83
  • -2.55 %
  • -$436.87
Dermata Therapeutics, Inc. (DRMA) Stock Price, News & Analysis

Dermata Therapeutics, Inc. (DRMA) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.56

$0.13

(9.09%)

Day's range
$1.43
Day's range
$1.64
50-day range
$1.29
Day's range
$5
  • Country: US
  • ISIN: US2498453065
52 wk range
$1.29
Day's range
$17.85


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -27.21
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (DRMA)
  • Company Dermata Therapeutics, Inc.
  • Price $1.56
  • Changes Percentage (9.09%)
  • Change $0.13
  • Day Low $1.43
  • Day High $1.64
  • Year High $17.85

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/07/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $6.00
  • High Stock Price Target $6.00
  • Low Stock Price Target $6.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$13.05
  • Trailing P/E Ratio -0.25
  • Forward P/E Ratio -0.25
  • P/E Growth -0.25
  • Net Income $-7,794,690

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.